We invite you to visit the IWMF website downloadable publications page, where you will find five new Treatment Options Guides. These Guides, based on the most recently published NCCN (National Comprehensive Cancer Network) and IWWM (International Workshops on WM) guidelines, review drug therapies and treatment guidelines currently used in the management of Waldenstrom’s macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.
These five guides – available in English, Traditional Chinese, Simplified Chinese, German, Italian, French and Spanish – are meant to update and replace the IWMF’s former Treatment Options booklet. They include:
Alkylating Agents and Nucleoside Analogs
This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).
Corticosteroids and Immunomodulators
This Guide includes corticosteroids, such as prednisone, prednisolone, and dexamethasone, as well as immunomodulators (IMiDs), such as thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidamide (Actimid or Pomalyst).
This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).
This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).
Targeted Therapies/Pathway Inhibitors
This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).